CJC-1295 without DAC

CJC-1295 Without DAC Research Peptide

CJC-1295 without DAC is a commonly used commercial designation for a shorter-acting GHRH(1-29)-type research peptide, often associated with the term Mod GRF 1-29.

The compound is studied in the context of growth hormone-releasing hormone (GHRH) receptor signaling, pituitary somatotroph biology, growth hormone secretion and the GH/IGF-1 endocrine axis.

Pure Axis Peptides offers CJC-1295 without DAC as a research-use peptide for qualified laboratory and scientific investigations.

What Is CJC-1295 Without DAC?

Growth hormone-releasing hormone, or GHRH, is a hypothalamic peptide that regulates growth hormone secretion from pituitary somatotroph cells.

GHRH and its synthetic analogues interact with the GHRH receptor (GHRHR) on pituitary cells. Activation of this receptor stimulates intracellular signaling involved in GH synthesis and secretion.

The term “without DAC” is important because the product does not incorporate the albumin-binding Drug Affinity Complex associated with the long-acting CJC-1295 molecule described in the primary pharmacological literature.

Published research identified DAC-containing CJC-1295 as an engineered GHRH analogue with prolonged albumin association and extended circulation.

Consequently, researchers should not assume that pharmacokinetic findings reported for CJC-1295 with DAC apply directly to a non-DAC GHRH(1-29)-type peptide.

CJC-1295 Without DAC and GHRH Research

GHRH is one of the principal hypothalamic regulators of growth hormone secretion.

Experimental GHRH analogues provide researchers with tools for investigating:

• GHRH receptor activation
• Pituitary somatotroph function
• Growth hormone secretion
• GH pulse regulation
• Hypothalamic-pituitary signaling
• IGF-1 biology
• Endocrine feedback mechanisms
• Peptide-receptor interactions

Studies of GHRH(1-29) analogues have demonstrated their ability to stimulate GH secretion in experimental and clinical settings. Earlier human research showed that GHRH(1-29)-NH₂ could stimulate GH release and was useful for investigating GH secretory capacity.

CJC-1295 Without DAC and Growth Hormone Research

Growth hormone is secreted by pituitary somatotrophs in a pulsatile pattern regulated by interactions among GHRH, somatostatin and other endocrine signals.

Shorter-acting GHRH analogues can be investigated to understand how receptor activation affects this physiological GH-secretion system.

This makes CJC-1295 without DAC relevant to research involving:

GH Secretion: Studying mechanisms controlling pituitary growth hormone release.

GHRH Signaling: Investigating activation of the GHRH receptor.

Pituitary Biology: Examining somatotroph-cell responses to GHRH analogues.

Endocrine Regulation: Studying interactions between hypothalamic and pituitary signals.

GH/IGF-1 Axis: Investigating relationships between GH secretion and downstream IGF-1 signaling.

GHRH Receptor Research

The GHRH receptor is a G-protein-coupled receptor expressed on pituitary somatotroph cells.

GHRH binding activates intracellular signaling pathways that increase GH synthesis and secretion.

Research involving GHRH analogues can therefore examine:

• Receptor activation
• Intracellular second-messenger signaling
• Somatotroph responsiveness
• GH gene expression
• Secretory dynamics
• Receptor desensitization
• Peptide structure-function relationships

This provides a molecular framework for studying the regulation of the GH axis without directly using recombinant growth hormone.

CJC-1295 Without DAC and GH Pulsatility

Growth hormone secretion is naturally episodic.

Experimental studies with GHRH have investigated how sustained or repeated receptor stimulation affects the amplitude and frequency of GH pulses. Human research has demonstrated that prolonged GHRH exposure can alter GH secretion dynamics and may produce reduced responsiveness under some experimental conditions, highlighting the importance of receptor and pituitary physiology.

This makes GHRH analogues useful tools for studying the mechanisms underlying pulsatile GH secretion and somatotroph responsiveness.

CJC-1295 Without DAC and IGF-1

The GH/IGF-1 axis links pituitary GH secretion with downstream endocrine and metabolic signaling.

Growth hormone stimulates production of IGF-1, particularly in the liver, although IGF-1 biology involves multiple tissues and regulatory mechanisms.

Research involving GHRH analogues can therefore examine the relationship between:

GHRH → GHRH receptor → GH → IGF-1

This pathway is an important subject of endocrine and metabolic research.

CJC-1295 Without DAC vs. CJC-1295 With DAC

The distinction between these terms is particularly important for researchers and should be clearly explained on the product page.

Characteristic	CJC-1295 Without DAC	CJC-1295 With DAC
Common research description	GHRH(1-29)-type analogue / Mod GRF terminology	DAC-modified CJC-1295
DAC modification	No	Yes
Albumin-binding extension	Not the defining feature	Defining feature
Research focus	GHRH receptor and GH signaling	Prolonged GHRH receptor stimulation
Pharmacokinetic profile	Shorter-acting	Extended
Best SEO terms	CJC-1295 without DAC, Mod GRF 1-29	CJC-1295 with DAC, CJC-1295 DAC

Published pharmacological work on CJC-1295 with DAC specifically describes an albumin-binding modification and prolonged circulation. Human studies subsequently demonstrated sustained GH and IGF-1 responses following the DAC-containing molecule.

Therefore, the two product pages should not share identical pharmacokinetic claims.

CJC-1295 Without DAC Research Applications

CJC-1295 without DAC may be relevant to laboratory studies involving:

• GHRH receptor biology
• Growth hormone research
• Pituitary somatotroph research
• GH secretion
• GH pulsatility
• IGF-1 signaling
• Hypothalamic-pituitary biology
• Endocrine pharmacology
• Peptide-receptor interactions
• GPCR signaling
• GHRH analogue research
• Structure-activity relationship studies
• Peptide pharmacokinetics

CJC-1295 Without DAC and Peptide Research

The non-DAC form is particularly useful as a research subject when investigators want to distinguish direct GHRH receptor signaling from the prolonged exposure created by albumin-binding modifications.

This distinction is valuable in comparative peptide studies examining how structural modifications affect:

• Receptor activity
• Peptide stability
• Circulating persistence
• GH responses
• Exposure duration
• Pharmacodynamic effects

The comparison between modified and unmodified GHRH analogues therefore provides a useful model for studying peptide engineering and pharmacokinetics.

Research Material

Researchers should verify the current Pure Axis Peptides product specification, peptide identity, purity, storage requirements and batch-specific certificate of analysis (COA) before laboratory use.

Because “CJC-1295 without DAC” and “Mod GRF 1-29” are sometimes used inconsistently in commercial peptide markets, analytical documentation is particularly important when establishing the identity of a research material.

Explore Related Research Peptides

CJC-1295 without DAC should form part of a broader growth-hormone research cluster.

Explore the Peptides collection for related research compounds.

Researchers can also compare this product with CJC-1295 with DAC to understand the distinction between DAC-modified and non-DAC GHRH research materials.

Other potentially relevant products in the GH-axis cluster include GHRP-6 and, where available, other GHRH or growth-hormone secretagogue research peptides.

Browse Research Chemicals for additional laboratory materials.

Visit Shop All Products for the complete Pure Axis Peptides catalog.

Research Use Only

CJC-1295 without DAC supplied by Pure Axis Peptides is intended strictly for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnosis, treatment, cure, or prevention of any disease or medical condition. Terminology such as “CJC-1295 without DAC” or “Mod GRF 1-29” should not be treated as interchangeable with the DAC-modified CJC-1295 molecule without verification of the specific material. Researchers should evaluate all materials according to their experimental requirements, product documentation and applicable laboratory procedures.

Internal Linking Recommendations

Primary Product Links

• CJC-1295 with DAC → https://pureaxispeptides.com/product/cjc-1295-with-dac/
• GHRP-6 Acetate → https://pureaxispeptides.com/product/ghrp-6-acetate/
• Peptides → https://pureaxispeptides.com/product-category/peptides/
• Research Chemicals → https://pureaxispeptides.com/product-category/research-chemicals/
• Shop All Products → https://pureaxispeptides.com/shop/

Recommended Internal-Link Anchors

Use varied, contextual anchors such as:

• “CJC-1295 with DAC”
• “DAC-modified CJC-1295”
• “GHRH research peptide”
• “GHRH receptor research”
• “growth hormone research peptide”
• “GH/IGF-1 research”
• “growth hormone secretagogue research”

Recommended Site Architecture

Build a dedicated GH-axis cluster:

CJC-1295 Without DAC
→ CJC-1295 With DAC
→ GHRP-6
→ other GHRH analogues
→ growth hormone secretagogues
→ Peptides category

The two CJC pages should link to each other prominently, with the anchor text making the DAC distinction explicit.

Verify the live WooCommerce URLs before publishing.

External Scientific References

• PubMed — CJC-1295 pharmacology and albumin-binding DAC modification:
  https://pubmed.ncbi.nlm.nih.gov/15817669/
• PubMed — CJC-1295 GH/IGF-1 pharmacodynamic study:
  https://pubmed.ncbi.nlm.nih.gov/16352683/
• PubMed — GH pulsatility and CJC-1295:
  https://pubmed.ncbi.nlm.nih.gov/17018654/
• PubMed — GHRH(1-29) analogue research:
  https://pubmed.ncbi.nlm.nih.gov/6236914/
• PubMed — GHRH analogue and GH response:
  https://pubmed.ncbi.nlm.nih.gov/7921207/
• PubMed — 2026 review of GH-axis research peptides:
  https://pubmed.ncbi.nlm.nih.gov/42395176/

Product Tags

CJC-1295 Without DAC, CJC 1295 Without DAC, CJC1295 Without DAC, CJC-1295 No DAC, CJC-1295 No DAC Peptide, CJC-1295 Research Peptide, CJC-1295 Research, CJC Without DAC, Mod GRF 1-29, Mod GRF 1-29 Peptide, Mod GRF Research, GHRH Peptide, GHRH Analogue, GHRH Research Peptide, GHRH Research, Growth Hormone Releasing Hormone, Growth Hormone Research, GH Research, GH IGF-1 Axis, IGF-1 Research, GHRH Receptor, GHRH Receptor Research, Pituitary Research, Somatotroph Research, Endocrine Research, GH Signaling, Peptide Pharmacology, Peptide-Receptor Research, Long-Acting Peptide Research, Laboratory Research